(NASDAQ: STOK) Stoke Therapeutics's forecast annual revenue growth rate of -13.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.37%.
Stoke Therapeutics's revenue in 2026 is $184,420,000.On average, 15 Wall Street analysts forecast STOK's revenue for 2026 to be $2,032,716,898, with the lowest STOK revenue forecast at $695,613,290, and the highest STOK revenue forecast at $4,347,583,065. On average, 12 Wall Street analysts forecast STOK's revenue for 2027 to be $3,700,473,422, with the lowest STOK revenue forecast at $2,052,059,207, and the highest STOK revenue forecast at $6,521,374,598.
In 2028, STOK is forecast to generate $7,535,810,646 in revenue, with the lowest revenue forecast at $4,214,257,184 and the highest revenue forecast at $13,359,205,922.